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ScienceDirectE3 ubiquitin ligase machineries are emerging as attractive
therapeutic targets because they confer specificity to substrate
ubiquitination and can be hijacked for targeted protein
degradation. In this review, we bring to focus our current
structural understanding of E3 ligase complexes, in particular
the multi-subunit cullin RING ligases, and modulation thereof
by small-molecule glues and PROTAC degraders. We highlight
recent advances in elucidating the modular assembly of E3
ligase machineries, their diverse substrate and degron
recognition mechanisms, and how these structural features
impact on ligase function. We then outline the emergence of
structures of E3 ligases bound to neo-substrates and degrader
molecules, and highlight the importance of studying such
ternary complexes for structure-based degrader design.
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Introduction
The ubiquitin–proteasome system (UPS) regulates pro-
tein homeostasis and is garnering increasing attention as a
therapeutic target owing to its role in several diseases
including cancer and neurodegeneration [1]. The post-
translational addition of ubiquitin to substrate proteins is
carried out sequentially by a cascade of three enzymes:
E1-activating enzyme, which activates ubiquitin (Ub) in
an ATP-dependent manner; E2-conjugating enzyme, to
which the activated Ub is transferred via trans-esterifica-
tion reaction; and E3 ubiquitin ligase, which catalyses the
transfer of Ub from the E2 to a lysine residue on the
substrate trough an isopeptide bond [2,3], althoughCurrent Opinion in Structural Biology 2021, 67:110–119 esterification reactions, for example, on threonine resi-
dues have been also reported [4].
E3 ubiquitin ligases can be branched into three classes:
homologous to E6-AP C-terminus (HECT), really inter-
esting new gene (RING) and RING-between-RING
(RBR) ligases [5]. HECT E3s accept ubiquitin (Ub) from
E2Ub to form a covalent thioester intermediate before
transferring it on to the substrate [6]. In contrast, RING
E3s brings E2Ub and substrate in close proximity to
each other to mediate a direct transfer of ubiquitin to the
substrate. The RBRs combine features of both HECT
and RING families, as the N-terminal RING domain first
recruits E2Ub conjugates and then transfers ubiquitin
on to a HECT-type C-terminal catalytic cysteine residue
before the final transfer on to the substrate [7]. Anaphase-
promoting complex (APC/C) is a large (1.2 MDa)
assembly of 11–13 proteins including a cullin (Apc2)
and RING (Apc11) subunit, and regulates different stages
of the cell cycle [8,9].
E3 ligases play a central role in imparting specificity to
substrate recruitment. E3 ligase ubiquitination activity
on native substrates is exquisitely controlled and regu-
lated by protein–protein interactions (PPI) dictating
their structural assembly. Furthermore, small-molecule
degraders such as molecular glues and proteolysis-tar-
geting chimeras (PROTACs) mediate recruitment of
non-native interacting proteins to E3 ligases, thus
hijacking the E3 intrinsic catalytic activity towards
neo-substrates for proteasomal degradation. Here we
review recent advances in elucidating the structural
basis of building and hijacking ubiquitination  machin-
eries, with a focus on Cullin RING E3 ligase assembly,
substrate recognition, and substrate recruitment medi-
ated by degraders that holds attractive therapeutic
potential.
Structural assembly and activity of modular
multi-subunit E3 ligases
Cullin RING E3 ubiquitin ligases (CRLs) represent the
largest family of E3 ligases. They are modular in that they
are composed of an interchangeable substrate receptor,
adaptor subunit(s), and a RING-box domain subunit,
assembled around a central cullin scaffold subunit. CRLs
are classified based on the type of cullin subunit
(Cul1, Cul2, Cul3, Cul4A, Cul4B, Cul5 and Cul7) [10].
Structures of fully assembled CRL complexes havewww.sciencedirect.com
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attained by the different cullin subunits [11].
The crystal structure of CRL2VHL complex, composed of
Cul2, RING-box protein (RBX1), Elongin B, Elongin C,
and von Hippel-Lindau protein (VHL) highlights an
inherent interdomain bending in Cullin scaffold proteins;
allowing the cullin C-terminal globular domain and the
N-terminal helical bundles domain to come closer in
space when compared to previously reported CRLFigure 1
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(a) E3 CRL assembly. Structural superposition of Cul2 (green, PDB: 5N4W [
bound Cul1 (orange, PDB: 1U6G [59]) and Cul4B (magenta, PDB: 4A0L [60]
highlights the flexibility of Cullin subunits. For CRL2VHL, ElonginB and RBX1
VHL (olive) from PDB: 1VCB [61] is superposed on PDB: 5N4W to show its 
structures. (b) NEDD8 (yellow)-activated CRL1b-TrCP–UBE2DUb–IkBa subs
and juxtaposed with the substrate. Zoomed section shows the isopeptide b
(green) winged-helix B (WHB), activating the CRL. b-TrCP (slate), SKP1 (gre
presenting the IkBa (magenta)-bound b-TrCP to the catalytic module. The c
(wheat) in the canonical closed activated conformation. (c) Macromolecular
components: Cul2 (violet), ElonginC (light orange), VHL (red) and NEDD8 (pa
releasing the heterodimer composed of CSN5 (wheat) and CSN6 (grey), foll
are shown in magenta, orange and slate, respectively. (d) Multi-subunit GID
binding site highlighted; GID1 (green), GID5 (magenta) and GID8 (yellow) ac
module. GID9 and GID2 ring domain is not modelled in the structure (PDB: 
shows the overall architecture of the assembly.
www.sciencedirect.com structures (Figure 1a) [12]. The structure also captures
the RBX1 RING domain in an intermediate step in the
full trajectory between inactive state and state activated
by post-translational modification with the ubiquitin-like
protein NEDD8 (neural precursor cell expressed devel-
opmentally downregulated protein 8) [12].
A recent cryo-electron microscopy structure captured a
snapshot of a stable intermediate state of neddylated
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esentation of each E3 ligase subunits with helices shown as cylinders.
12]), NEDD8-modified Cul1 (light blue, PDB: 6TTU [13]), CAND1-
) along the C-terminal domain (CTD) of Cul2 (residues 386–745)
 subunits bound to Cul2 are shown in cyan and slate, respectively.
location. For clarity only the cullin subunit is shown for the other CRL
trate intermediate (PDB: 6TTU [13]), in which UBE2DUb is activated
ond between the terminal glycine of NEDD8 (yellow) and K720 of Cul1
y), and Cul1 (green) contribute as substrate scaffolding module
atalytic module is composed of UBE2D(cyan)Ub(orange)–RBX1
 structure of CSN–CRL2–NEDD8 (PDB: 6R7F [14]). CRL2-NEDD8
le green). CSN2 (cyan) and CSN4 (yellow) clamp the Cul2 (violet)
owed by deneddylation by CSN5. CSN3, CSN7B and CSN8 subunits
 E3 assembly: GID4 (cyan) acts as the substrate receptor, substrate
t as scaffolding module; GID2 (wheat) and GID9 act as catalytic
6SWY [21]). Schematic diagram of the GID complex in the right
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activation. The structure comprises of neddylated
CRL1b-TRCP, ubiquitin-loaded E2 ubiquitin-conjugating
enzyme UBE2D, and a phosphorylated peptide from
IkBa (nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha) (Figure 1b) [13].
The full structure captures three distinct modules. First,
NEDD8 is covalently linked to the winged helix-B
(WHB) domain of cullin to form a globular activation
module. Second, the catalytic module consists of ubiqui-
tin-bound UBE2D and the RING domain of RBX1.
Third, a so-called ‘substrate-scaffolding module’ compris-
ing substrate receptor b-TRCP, adaptor subunit S-phase
kinase-associated protein 1 (SKP1), and Cul1 together
presents the b-TrCP-bound IkBa substrate towards the
catalytic module. The mobile WHB domain of Cul1
permits the activation module to form multiple contacts
between the ‘backside’ of UBE2D in the catalytic mod-
ule and Cul1 in the substrate-scaffolding module. These
extensive interactions facilitate the catalytic centre of
UBE2D to be placed in proximity to the b-TRCP-bound
substrate for subsequent ubiquitination.
Like ubiquitination, neddylation is also a reversible pro-
cess. The deneddylation process is catalysed by the
COP9 signalosome (CSN), an eight-subunit protein com-
plex. A recent cryo-EM structure of the CSN tightly
bound to neddylated CRL2VHL adds to the structural
details from the previous structures of CSN interaction
with CRL1, CRL3 and CRL4A (Figure 1c) [14,15,16].
The structure reaffirms the conserved activation mecha-
nism of the deneddylation machinery, including confor-
mational clamping of CRL2 by CSN2/CSN4, release of
the catalytic CSN5/CSN6 heterodimer, and subsequent
activation of the metalloprotease CSN5 [14]. More
recently, inositol hexakisphosphate (IP6) has been char-
acterized as a CSN cofactor that enhances interaction
between CSN2 and RBX1, mediating CSN sequestration
of CRL4 from UBE2R to prevent CRL4 activation [17].
The eukaryotic N-end rule pathway was traditionally
classified into the Arg/N-end rule (recognising N-termi-
nal basic/bulky/arginylated Asp and Glu residues) path-
way and the Ac/N-end rule pathway (recognising N-
terminal acetylated residues) [18]. Glucose-induced deg-
radation subunit 4 (GID4) represents the subunit of GID
assembly ubiquitin ligase that recognises substrates har-
bouring a recently identified third branch of N-end
degron, Pro/N-degrons [19]. GID is a multisubunit E3
ligase from yeast that recognises the N-terminal proline of
gluconeogenic enzymes and catalyses their ubiquitina-
tion (Figure 1d) [20]. The GID assembly assumes an
anticipatory state GIDAnt under carbon stress. With car-
bon recovery, glucose-induced expression of Gid4 transi-
tions GIDant into active GIDSR4 recognizing isocitrate
lyase (Icl1), fructose -1,6-bisphosphatase (Fbp1), and
malate dehydrogenase (Mdh2) substrates [21]. The roleCurrent Opinion in Structural Biology 2021, 67:110–119 of different subunits in GID assembly can be clustered as
catalytic module (GID2 and 9), scaffold module (GID1,8
and 5) and substrate receptor module (GID4 or 10). The
eight b strands and four loops of GID4 b-barrel forms a
narrow opening with the N-terminal proline filling snugly
in the central cavity (Figure 2a). The selectivity for
proline recognition is imparted by a tight network of
hydrogen bonds and hydrophobic interactions [19].
GID10 is proposed to be a substrate receptor that is
expressed only under osmotic stress, although its sub-
strate remains to be identified.
Substrate recognition by E3 ligase substrate
receptors
CRLs employ a substrate receptor module to provide
specificity for substrate recognition [10,11,22]. This sec-
tion focuses on recent advances in the understanding of
the structural basis of the highly diverse substrate recog-
nition by E3 CRLs. The CRL1FBXL5 — iron regulatory
protein 2 (IRP2) complex structure provides insight into
the oxygen sensing role of the [2Fe2S] cluster in binding
to IRP2 (Figure 2b) [23]. [2Fe2S] acts as a cofactor by
forming coordination bonds with the conserved cysteines
of F-Box and Leucine Rich Repeat Protein 5 (FBXL5),
presenting the ‘interface loop’ of leucine rich repeat
(LRR) domain to IRP2 domain IV [23].
The CRL2 subunit Kelch domain-containing protein 2
(KLHDC2) was recently found to recognise substrates via
a novel C-end degron protein-degradation mechanism,
named DesCEND (destruction via C-end degron)
[24,25]. The crystal structure of KLHDC2 in complex
with C-terminal diglycine degrons of early terminated
selenoproteins SelK and SelS, and N-terminal proteolytic
fragment of USP1 reveals a deep and basic pocket at the
centre of the Kelch domain of KLHDC2 that recognises
the substrate via a network of hydrogen bonding inter-
actions with its terminal carboxyl group, achieving nano-
molar binding affinities (Figure 2c) [24].
Unlike other cullins, CRL3 substrate receptors harbour
substrate binding domain [kelch, or meprin and TRAF
homology (MATH)] and adaptor domain [bric-a-brac/
tramtrack/broad complex (BTB)] in a single polypeptide.
Kelch-like protein 12 (KLHL12) and Kelch-like protein
20 (KLHL20) belong to substrate receptors with a Kelch
domain. Two recent studies on KLHL12 characterize
‘PGXPP’ as the degron motif from substrate protein
Dishevelled (Figure 2d) [26,27]. The structures reveal
a U-shaped turn conformation of bound substrates in the
KLHL12 hydrophobic pocket. In contrast, the ‘LPDLV’
Death-associated protein kinase 1 (DAPK1) epitope
binds the Kelch-like protein 20 (KLHL20) as a loose
helical turn (Figure 2e) [28]. The differential selectivity
across the CRL3 Kelch domains could be attributed to
variable length of loops at the top of the propeller and
differences in patterns of hydrophobic and chargedwww.sciencedirect.com
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Substrate recognition by E3 ligase substrate receptors: (a) GID4 (pale green cartoon) antiparallel b-barrel loops form a narrow groove to recognise
N-Proline peptide (cyan carbon sticks) shown as surface (PDB: 6CDC [19]). (b) SKP1 (magenta) and FBXL5 (cyan) of CRL1FBXL5 represented in
cartoon and transparent surface, interacting with substrate iron response protein 2 (IRP2, green cartoon). Cofactor 2Fe2S, depicted in spheres,
mediates the interaction between the FBXL5 leucine rich repeat (LRR) domain and IRP2 domain IV (PDB: 6VCD [23]). (c–e) Electrostatic surface
potential map (positive in blue and negative in red) of Kelch repeat domains in complex with substrate degron peptides, shown in sticks. (c) SelK
(magenta) C-terminus forming a helix and fitting into the positively charged groove of KLHDC2 (PDB: 6DO3 [24]). (d) Dvl3 (magenta) and Dvl1
(green) peptides display similar U-turn conformations while interacting with the hydrophobic pocket of KLHL12 (PDB: 6V7O [26], 6TTK [27]). (e)
DAPK1 (cyan) forming a loose helical turn while interacting with KLHL20 (PDB: 6GY5 [28]). (f) Surface view of SPOP MATH domain (pale green
cartoon) bound to substrates Pdx1 (cyan carbon sticks), MacroH2A (yellow ribbon) and Puc (wheat ribbon) (PDB: 6F8F [29], 3IVB and 3IVV [30],
respectively). (g) Kinase inhibitory region (KIR) domain of SOCS1 (cyan cartoon) interacting with JAK1 (pale green cartoon) substrate binding
groove (PDB: 6C7Y [31]). (h) Surface view of SOCS2 (light orange) SH2 domain bound with erythropoietin receptor (EpoR) degron peptide (green
carbon sticks) (PDB: 6I4X [32]). (i) Surface view of ASB9 (magenta cartoon) in complex with CKB dimer (light orange and light blue cartoon) (PDB:
6V9H [34]).residues. Speckle-type POZ protein (SPOP) is an exam-
ple of CRL3 substrate receptor protein that utilises
MATH domain to bind its substrates. The cocrystal
structure of pancreas/duodenum homeobox protein 1
(Pdx1) bound to SPOP-MATH relaxes the consensus
binding motif for previously characterized SPOP ligands
Puc phosphatase and MacroH2A (F-p-S-S/T-S/T, F:non-
polar; p: polar) to (F-p-S-p-p) (Figure 2f) [29,30].
CRL5 substrate-bound structures of suppressor of cyto-
kine signaling 1 (SOCS1), suppressor of cytokine signal-
ing 2 (SOCS2) and ankyrin repeat and SOCS box protein
9 (ASB9) substrate recognition modules have been
recently solved. SOCS1 and SOCS2 share a similar
domain architecture comprising of an N-terminal
extended SH2 subdomain (ESS), a central Src-homologywww.sciencedirect.com 2 (SH2) domain that recognises a phosphotyrosine (pY)
containing sequence, and SOCS box that interacts with
the adaptor ElonginB-ElonginC complex (EloBC). The
ability of SOCS1 to recruit Cul5 and function as an E3
ligase is compromised because of alterations in the Cullin
binding region of its SOCS box. An additional kinase
inhibitory region (KIR) domain helps SOCS1 inhibit
Janus kinase (JAK1 and JAK2) catalytic activity by block-
ing its substrate binding groove (Figure 2g) [31]. Inter-
actions between JAK ‘GQM’ motif and BC loop of
SOCS1 SH2 domain further augments binding affinity.
SOCS2 utilises the SH2 domain to recognise phosphode-
grons from erythropoietin receptor (EpoR) and growth
hormone receptor (GHR) (Figure 2h) [32]. Unlike in
SOCS3 and SOCS6 where the BG loop closes-in over the
substrate to form a hydrophobic channel, the loop inCurrent Opinion in Structural Biology 2021, 67:110–119
114 Macromolecular assembliesSOCS2 adopts an open conformation that accommodates
a wider range of lower-affinity substrates. ASB9 belongs
to the largest family of SOCS box containing receptors,
with ankyrin repeats serving as the recognition module
[33]. A cryo-EM structure of ASB9 bound to the homo-
dimer of Creatine Kinase brain type (CKB) substrate
reveals that ASB925–34 form a helix-turn that inserts into
a pocket formed by acidic D32 and basic residues (R132,
N286, R292, R341) at the interface of the CKB homo-
dimer (Figure 2i) [34].
Small-molecule glues of E3 ligase:neo-
substrate interactions
Molecular glues mediate de novo PPIs between an E3
ligase and a neo-substrate protein leading to polyubiqui-
tination and subsequent degradation of that protein. A
first notable example of E3-ligase directed molecular
glues is the plant hormone auxin that mediates
CRL1TIR1-mediated degradation of transcription repres-
sors [35]. Prominent examples of non-natural molecular
glues are thalidomide and its Immunomodulatory drugs
(IMiDs) analogues lenalidomide and pomalidomide.
IMiDs bind to CRL4CRBN and subsequently ‘glue’ lym-
phoid transcription factors Ikaros and Aiolos as neo-sub-
strates, leading to their proteasomal degradation [36–38].
Crystal structures of DNA damage-binding protein 1
(DDB1)–cereblon (CRBN) complex bound to IMiDs
and either casein kinase (CK1a) or G1 to S Phase Tran-
sition 1 (GSPT1) as neo-substrates provided structural
insights into the mechanism of IMiD-mediated modula-
tion of CRBN substrate specificity [36,39]. Recent com-
plex structures of CRBN and pomalidomide with the
second zinc finger (ZF2) of Ikaros (IKZF1), zinc finger
protein 692(ZNF692) ZF4, and spalt like transcription
factor 4 (SALL4) ZF2 highlight that in spite of minimal
sequence conservation in the zinc finger degrons, poma-
lidomide can mediate a conserved binding mode
[40,41]. An overlay of the complex structures highlight
how a strictly conserved glycine of the ZF b-hairpin loop
degron docks into a binding hotspot at the CRBN-poma-
lidomide interface (Figure 3a). These structural insights
can now guide the rational design of higher-affinity
CRBN binders, including molecular glues with enhanced
potency and specificity for improved degradation of neo-
substrate proteins [42].
Molecular glues have also been purposefully developed
to enhance native E3 ligase-substrate PPIs, otherwise
weakened in disease state, for example, as a result of
mutations, thus rescuing impaired degradation of sub-
strate protein [43]. The phosphodegron (DpSGwXpS) of
oncogenic transcription factor b-catenin is recognised by
CRL1b-TrCP via phosphorylated Ser33 and Ser37, lead-
ing to efficient CRL1b-TrCP-dependent ubiquitination
and degradation of b-catenin. In many cancers, this PPI
is significantly weakened as a result of mutations, for
example, Ser-to-Ala or decreased phosphorylationCurrent Opinion in Structural Biology 2021, 67:110–119 levels — suggesting a strategy for rescuing the PPI via
a small-molecular glue approach. Focused screening for
enhanced PPI, followed by structure-guided design,
achieved molecular glue NRX-2663 that enhanced the
binding affinity of unphosphorylated Ser33/S37A b-cate-
nin for b-TrCP by >10 000-fold. Ternary complex struc-
ture of NRX-2663 with monophosphorylated pSer33
b-catenin peptide and b-TrCP/Skp1 reveals that a por-
tion of NRX-2663 fills the space left by unphosphory-
lated Ser37, thus substituting for the missing phosphate
group (Figure 3b) [43].
Aryl-sulfonamide (e.g. indisulam) anticancer drugs were
found to function as molecular glues to the CRL4 sub-
strate receptor DDB1-associated and CUL4-associated
factor 15 (DCAF15), leading to ubiquitination and pro-
teasomal degradation of splicing factor RNA Binding
Motif Protein 39 (RBM39), via a mechanism akin to that
of IMiDs [44,45]. The structural basis of sulfonamide
mode of action was recently elucidated in three indepen-
dent structural-biophysical studies of sulfonamide-medi-
ated complexes between DDB1–DCAF15 and RBM39
(Figure 3c) [46,47,48]. Indisulam and sulfonamide
analogues occupy a shallow groove at the interface
between the C-terminal and N-terminal domains of
DCAF15, with the two sulfonyl oxygens forming hydro-
gen bonds with the backbone amide nitrogens of
DCAF15 A234 and F235. In addition, the indole nitrogen
and sulfonamide nitrogen form extensive water-mediated
hydrogen bonds with the side-chain oxygens of RBM39
T262 and D264 (Figure 3c).
Unlike traditional molecular glues that bind to the sub-
strate receptor subunit/domain of E3 ligases, a new class
of glue-like compounds recruit E3 ligase machineries
once bound to their target protein. The protein kinase
inhibitor CR8 was shown to mediate binding of its target
cyclin-dependent kinase 12 (CDK12) and the associated
partner protein CyclinK to the CRL4 adaptor subunit
DDB1. As a result, CDK12 acts as a neo substrate-recog-
nition subunit (Figure 3d) [49]. CDK12 forms extensive
interactions with BPA, BPC and C-terminal domains of
DDB1, occupying the same position in the assembly as
that of a substrate-recognition subunit. Similar to the N-
terminus of DCAF15, the C-terminal tail of CDK12 binds
to the cleft between the BPA and BPC domains of DDB1.
Cyclin K, which binds CDK12 on the opposite side of
CDK12, does not contact DDB1 and is presented as a neo-
substrate, suitably positioned for ubiquitination and sub-
sequent degradation (Figure 3d). More recently, Mayor-
Ruiz et al. performed a focused compound screening in
wild type versus isogenic hyponeddylated cells as an
approach to enrich for hits that require functional ubiqui-
tination machineries for their cellular activity [50]. Their
screenings identified small molecules that glued between
CDKs and DDB1, despite being chemically diverse to
CR8.www.sciencedirect.com
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Figure 3
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Ternary complexes of E3 ligases with molecular glue degraders: (a–d) E3 ligase is displayed as 40% transparent surface and cartoon
representation; substrate is displayed as cartoon and molecular glue is shown as spheres. Zoomed section of the interaction interface shows
molecular glue in sticks with key hydrogen bond and cation-p interactions shown in yellow and orange dashed lines, respectively. (a) Superposed
crystal structures of CRBN(wheat)–DDB1(cyan)–pomalidomide(purple blue carbons) bound to IKZF1 ZF2 (yellow), ZNF692 ZF4 (magenta) and
SALL4 ZF2 (green) (PDB: 6H0F [40], 6H0G [40], 6UML [41]). Alignment of structures is performed along the CRBN-CTD. Zoomed section of the
interaction interface shows the hairpin loop of the SALL4 ZF2, pomalidomide and interacting residues from CRBN in sticks. (b) Ternary complex of
b-TrCP (grey), monophosphorylated b-catenin degron peptide (magenta) and NRX-2663 (green carbons) (PDB: 6M92 [43]). Doubly phosphorylated
b-catenin peptide (yellow) is superposed to highlight the void occupied by NRX-2633 created by the absence of a phosphate group in Ser37
(PDB: 1P22 [62]). Zoomed section displays NRX-2663 and b-catenin shown in sticks. (c) Crystal structure of DCAF15(green)–DDB1(cyan)–DDA1
(yellow) in complex with indisulam (orange carbons) and RBM39 (magenta) (PDB: 6UD7 [46]). Zoomed section shows indisulam interacting
residues from RBM39 and DCAF15 in sticks. Water molecules mediating protein-ligand interactions are displayed as small red spheres. (d) Crystal
structure of CDK12(yellow)–cyclinK(magenta) with bound CR8 (orange carbons) and DDB1 (cyan) (PDB: 6TD3 [49]). The C-terminal extension of
CDK12 docks into a cleft between the DDB1 domains BPA and BPC, in a manner similar to how the DCAF15 N-terminal tail (and other CRL4
substrate receptors) insert in the same cleft. Zoomed section focusing on the interaction interface between DDB1, CR8 and CDK12.PROTACs: bifunctional small molecules
bridging target proteins to E3 ligases
PROteolysis TArgeting Chimeras (PROTACs) are
bifunctional degrader molecules made of an E3 ligase
ligand and a target protein ligand, joined by a chemical
linker [51,52]. PROTACs can bind to E3 ligase or target
protein independently (1:1 complex), before inducing
proximity between the two proteins in the form of a
ternary complex (1:1:1 complex). Because of their chem-
ical nature, PROTACs differentiate from molecular
glues, which lack a linker and can bind to one but not
the other of the two proteins. For these reasons, PRO-
TACs were thought of working independently of PPIswww.sciencedirect.com between the ligase and the targeted protein. This notion
has dramatically changed thanks to emerging structural
and biophysical insights into PROTAC ternary com-
plexes, revealing PROTACs can also ‘glue’ E3 ligase
and target protein into stable and cooperative ternary
complexes.
Our group solved a first PROTAC ternary structure,
composed of our previously discovered PROTAC
MZ1, a degrader of the Bromodomain and extraterminal
domain (BET) protein Brd4, bound to VHL–ElonginC–
ElonginB (VCB) and second bromodomain of Brd4
(Brd4BD2) (Figure 4a) [53]. The crystal structure revealedCurrent Opinion in Structural Biology 2021, 67:110–119
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Crystal structures of E3 ligase-PROTAC-Target protein ternary complexes: (a–d) E3 ligase is displayed as 40% transparent surface and cartoon,
substrate is displayed as cartoon and PROTAC is shown as spheres. Zoomed section of the interaction interface shows PROTAC in sticks, and
surface representation of both E3 ligase and target protein. (a) Crystal structure of VHL(orange)-ElonginC(magenta)-ElonginB(yellow) (VCB) in
complex with MZ1 (cyan) and Brd4BD2 (pale green) (PDB: 5T35 [53]). Zoomed section shows the structure-based rational design of
MacroPROTAC-1 (yellow carbon sticks) from MZ1 (PDB: 6SIS [55]). The bioactive conformation of the linker is locked in MacroPROTAC-1 by
cyclising the molecule through linkage of the phenolic group on the VHL ligand and a methylene group adjacent to the BET ligand’s amide bond.
(b) Crystal structure of VCB in complex with PROTAC 1 (cyan) and SMARCA2BD (dark green) (PDB: 6HAY [56]). Zoomed section shows the
structure-based design of PROTAC 2 (PDB: 6HAX [56]) aimed at rigidifying the linker through substitution of a flexible 5-atom portion of the linker
with a phenyl ring. (c) Ternary complex of VCB–PROTAC6(cyan)–Bcl-xL(lime green) (PDB: 6ZHC [57]). (d) Crystal structure of CRBN(violet)–DDB1
(green) complex with bound PROTAC dBET23 (cyan) and Brd4BD1 (magenta) (PDB: 6BN7 [58]).non-native neo-PPIs between VHL and Brd4BD2, of both
hydrophobic and hydrophilic nature, wrapping the PRO-
TAC into a collapsed yet favourable conformation, and
resulting in the burial of extensive surface area in the
system. The induced PPIs are isoform-specific and con-
tribute to the formation of highly cooperative (a  20),
stable and long-lived (t1/2 > 2 min) ternary complex with
Brd4BD2, which drive more pronounced ubiquitination
and faster degradation of Brd4 in cells [53,54]. With the
ternary structure in hand, rational structure-based
approaches can be undertaken to design improvedCurrent Opinion in Structural Biology 2021, 67:110–119 PROTAC degraders. On the basis of the MZ1 ternary
structure, Gadd et al. first designed a novel linkage point
and conjugation vector on the VHL binding portion of
MZ1, achieving PROTAC degrader AT1 which exhib-
ited improved Brd4-degradation selectivity over MZ1.
More recently, Testa et al. hypothesized that cyclisation
of the PROTAC would lock MZ1 preferentially in its
bioactive conformation. Aided by structure-based compu-
tational studies, macrocyclic PROTAC degrader Macro-
PROTAC-1 was designed by adding a cyclizing linker
onto MZ1 (Figure 4a). MacroPROTAC-1 showedwww.sciencedirect.com
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12-fold in binding affinity to Brd4BD2 [55].
Another example of successful application of rational
structure-based design applied to PROTACs is the devel-
opment of degraders of SWI/SNF Related, Matrix Asso-
ciated, Actin Dependent Regulator Of Chromatin, Sub-
family A (SMARCA2 and SMARCA4) [56]. An early,
poor degrader of SMARCA2 (PROTAC 1), formed a
cooperative ternary complex with VHL (a  10) despite
its weak (mM) binding affinity for SMARCA2. This
observation suggested that high-resolution structure
could allow rapid optimization. Ternary complex co-crys-
tal structure revealed extensive de novo PPIs contributing
favourable binding energy, as in the case of MZ1, how-
ever accommodated through an unfavourably collapsed
linker. Armed with this information, the linker was rigid-
ified upon replacement of one of its PEG unit with a
phenyl group, allowing formation of an additional
p-stacking interaction with VHL Y98 (Figure 4b). Fur-
ther optimization led to potent SMARCA2/4 degrader
ACBI1 that formed ternary complexes of improved coop-
erativity and stability.
Ligase-PROTAC-target complexes have also been
solved for systems that do not appear to exhibit positive
cooperativity in the ternary equilibria, suggesting avenues
for potential optimization strategy. The recent structure
of a VCB:PROTAC6:B-cell lymphoma-extra-large (Bcl-
xL) complex shows the long PEG linker of PROTAC6 is
forced to adopt an extended conformation, before folding
back into itself via a compact turn (Figure 4c) [57]. The
unfavourable linker conformational energy likely sur-
passes any favourable induced PPIs, resulting in the
negative cooperativity observed with this system. Relax-
ing such conformation while maintaining the relative
geometry of the ternary complex might lead to improved
Bcl-xL PROTAC degraders. Nowak et al. structurally
characterized non-cooperative ternary complexes formed
by CRBN-recruiting JQ1-based PROTACs (dBETs) of
varying linker lengths (10–34 atoms) and conjugation
points (Figure 4d) [58]. Distinct arrangements of the
CRBN–Brd4 interface with different PROTACs
highlighted plasticity of the interaction. These structural
studies suggest that ternary systems of suboptimal energy
and stability may still be productive for targeted protein
degradation, if made of high-affinity protein binding
ligands.
Conclusions
We have reviewed recent developments in structural
understanding of assembly, function and (neo)-substrate
recognition of E3 ligases. Existence of over 600 E3 ligases
in mammalian cells underscore their importance in fine-
tuning substrate specificity as a regulatory mechanism of
protein homeostasis. E3 ligases are emerging as attractive
drug targets in their own right because of their implicationwww.sciencedirect.com and dysregulation in several diseases. Therapeutic exploi-
tation of E3 ligases with small molecules requires a
structural and mechanistic understanding of the interplay
of protein-protein interactions between their component
subunits and how they impart biological function.
For drug development, knowledge of substrate-bound
structures of E3 ligases can guide the development of
small-molecule inhibitors. The advent of protein degra-
ders that glue to E3 ligases and hijack E3 catalytic activity
to effect targeted degradation of intracellular disease-
driving proteins are motivating augmented efforts focus-
ing on this family class. Recent years have watched the
emergence of structures solved for E3 ligases with molec-
ular glue/PROTAC degraders and neo-substrates bound.
The structures highlight the growing impact of structural
and biophysical understanding of E3 ligase ternary com-
plexes for degrader drug design. These founding
advances are motivating current efforts to discover small
molecules for more E3 ubiquitin ligases. This has the
potential to usher the development of inhibitors or degra-
ders that leverage a wider range of cell-specific, tissue-
specific and disease-specific expression as well as func-
tional essentiality and redundancy of E3 ligases, aiding
improved therapeutics in the future.
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